Life Sciences

  • March 11, 2026

    Biomedical Co. Settles Trade Secrets Case Against Ex-Worker

    Biomedical company Skye Orthobiologics and a former employee have informed a California federal judge that they have settled a case accusing the ex-employee of breaching fiduciary duties by leveraging Skye's proprietary information.

  • March 11, 2026

    Investor Urges Revival Of Armistice Insider Trading Claims

    The Delaware Supreme Court has heard arguments over whether a hedge fund that traded tens of millions of dollars' worth of stock can face insider trading liability under state law after its board designee allegedly received confidential company information, with an Aytu BioPharma shareholder urging the court to revive claims against healthcare investor Armistice Capital.

  • March 10, 2026

    Justices Advised To Keep Law Clear In 'Skinny Label' Case

    Several intellectual property groups have urged the U.S. Supreme Court to use a case involving "skinny labels" on generic drugs to set clear guidelines on what constitutes induced patent infringement, saying the outcome has implications beyond pharmaceuticals.

  • March 10, 2026

    J&J Unit Wins Sanction In Talc Libel Case

    A Virginia federal judge on Tuesday issued sanctions against a doctor being sued by a Johnson & Johnson unit over an article linking mesothelioma with talc products, saying that a jury will be told that he deleted emails about the article when he was legally obligated to keep them.

  • March 10, 2026

    5th Circ. Revives J&J Sales Rep's Wage Dispute

    A Texas federal court did not take into consideration relevant factors to determine whether a former Johnson & Johnson sales representative's failure to retain local counsel in his wage and hour suit represented excusable neglect, the Fifth Circuit ruled on Tuesday.

  • March 10, 2026

    Sanofi Says Judge Botched Insulin Device Patent Listings

    Sanofi-Aventis sparred with drug wholesalers over a Massachusetts federal magistrate judge's pronouncements that the parties should go to trial on claims the pharmaceutical giant used improper insulin device patent listings to anticompetitively protect the blockbuster Lantus insulin pen from competition.

  • March 10, 2026

    Lab's Aetna Payment Suit Survives, But With Deep Cuts

    A Connecticut federal judge ruled Aetna and its parent company, CVS Health Corp., must face a pared down lawsuit from a medical laboratory alleging it is owed $20.6 million in unpaid invoices.

  • March 10, 2026

    FDA To Consider Coffee, 'Spice' E-Cig Flavors

    The U.S. Food and Drug Administration on Monday indicated that it would be willing to consider e-cigarette flavors shown to be less attractive to youth, like coffee or spices, a move that's come under fire from public health advocates.

  • March 10, 2026

    CVS Can't 'Relitigate' Price-Gouging Class Cert.

    A Rhode Island federal judge refused to narrow the certified classes of health plans alleging CVS schemed with pharmacy benefit managers to overcharge insured health plans for generic drugs, finding that PBM Express Scripts' refusal to produce its contracts changes nothing about how the classes will be assessed.

  • March 10, 2026

    Former Conn. Prosecutor Can Stay On Generic-Drug Case

    Connecticut's former assistant attorney general can continue to represent insurers Humana and Molina Healthcare Inc. in multidistrict litigation over alleged price-fixing of generic drugs, after the Pennsylvania federal judge overseeing the case agreed Monday with a report that the attorney has no information that had not already been shared.

  • March 10, 2026

    Medtronic Expands Vascular Device Line With $550M Deal

    Medtronic said Tuesday it will acquire privately held Scientia Vascular for about $550 million, strengthening its portfolio of devices used to treat stroke and other neurovascular conditions.

  • March 10, 2026

    J&J Opposes Beasley Allen Reinstatement Bid In NJ Talc Fight

    Johnson & Johnson is urging the New Jersey Supreme Court to not take the "extraordinary step" of intervening in an appellate panel ruling that disqualified Beasley Allen from representing hundreds of women in product liability litigation against the pharmaceutical giant after the Georgia-based firm "knowingly collaborated" with a former Johnson & Johnson outside counsel.

  • March 09, 2026

    Texas AG Gets Temporary Ban On Chest Binder Sales

    A Texas state judge has issued a temporary restraining order against a New York-based online retailer of undergarments and chest binders for young women and teens from selling its clothing in the Lone Star State.

  • March 09, 2026

    Abortion Rights Group, SD Agree to End Gas Station Ads Row

    An abortion rights group can no longer post advertisements at gas stations in South Dakota that promote abortion care, the South Dakota attorney general's office announced on Monday, saying that the group and the state have reached an agreement in a pair of lawsuits over the advertising campaign. 

  • March 09, 2026

    Novo, Hims & Hers Make Up, Agree To Sell GLP-1s Together

    Novo Nordisk A/S will start selling its GLP-1 medications on Hims & Hers Health Inc.'s platform as part of a deal that resolves the pharmaceutical company's patent infringement lawsuit against the telehealth provider, the companies announced Monday.

  • March 09, 2026

    Biopharma Brass Hid Drug Trial Risks, Derivative Suit Says

    Brass of Ultragenyx Pharmaceutical Inc. are facing shareholder derivative claims they caused the company to overstate prospects for a drug to treat a bone disease, hurting investors and opening the company up to liability when its share prices fell following disappointing clinical trial news.

  • March 09, 2026

    Astellas Prevails In Patent Battle Over Bladder Drug

    A Delaware federal judge has held that Ascent Pharmaceuticals infringed four patents covering bladder medication Myrbetriq held by name-brand drugmaker Astellas Pharma Inc. and rejected Ascent's invalidity defenses.

  • March 09, 2026

    McGuireWoods Beats Sun Pharma's DQ Bid In NJ Suit

    A New Jersey federal court has denied Sun Pharmaceutical's bid to disqualify McGuireWoods LLP from representing pharmaceutical company Biofrontera in litigation over the alleged breach of a settlement agreement, ruling the firm's continued representation won't harm Sun Pharmaceutical and will avoid significant harm to Biofrontera.

  • March 09, 2026

    Sullivan & Cromwell Advises Agilent On $950M Biocare Buy

    Agilent Technologies Inc. agreed to acquire Biocare Medical, a specialist in clinical and research pathology solutions, in an all-cash transaction valued at $950 million, the company said Monday.

  • March 09, 2026

    JPMorgan Trims But Can't Escape ERISA Drug Costs Suit

    A New York federal judge pared claims Monday against JPMorgan Chase & Co. in a suit from workers who alleged they paid too much for prescription drugs, but opened discovery on allegations that the bank's contract with its pharmacy benefit manager caused transactions prohibited by federal benefits law.

  • March 06, 2026

    Atty Should've Checked Docket, Says Philips CPAP Judge

    An attorney and his client have no one but themselves to blame for the permanent end to a product liability lawsuit over a recalled Philips sleep breathing machine, a Pennsylvania federal judge said on Friday, saying it was on them to monitor the docket.

  • March 06, 2026

    ExThera Exec Hid Patient Deaths To Keep $10M Deal, DOJ Says

    Medical device company ExThera concealed the deaths of two U.S. patients treated with its unapproved blood filtration device at a clinic in Antigua, according to federal prosecutors, with the company agreeing to forfeit nearly $5.7 million and one executive facing up to three years in prison.

  • March 06, 2026

    FDA Vaccine Chief Prasad To Exit Agency For 2nd Time

    Dr. Vinay Prasad, the U.S. Food and Drug Administration's top vaccine regulator, will leave the agency in the coming weeks, FDA Commissioner Marty Makary said Friday.

  • March 06, 2026

    Drugmaker Nektar Faces Suit Over Hair Loss Drug Trial Claims

    Pharmaceutical company Nektar Therapeutics on Friday was hit with a proposed class action accusing it of harming investors by failing to disclose the risks associated with its failure to follow protocol for enrolling participants in an unsuccessful trial for its hair loss treatment.

  • March 06, 2026

    Actelion Pays $65M To Settle Tracleer Antitrust Class Suit

    Actelion Pharmaceuticals Ltd. agreed to pay $65 million to resolve antitrust claims from a certified class accusing it of illegally denying generics companies the samples they need to produce generic versions of its hypertension drug Tracleer, according to a brief in Maryland federal court seeking preliminary approval of the settlement.

Expert Analysis

  • Patent Applicants Must Get Biologics Enablement Right

    Author Photo

    As artificial intelligence increasingly becomes a core driver in drug discovery, it is critical for drug companies to adapt their drafting strategies to the unique features of AI-generated inventions, and to pay particularly close attention to enablement standards, says Sanandan Malhotra at Novo Nordisk.

  • Series

    Law School's Missed Lessons: How To Start A Law Firm

    Author Photo

    Launching and sustaining a law firm requires skills most law schools don't teach, but every lawyer should understand a few core principles that can make the leap calculated rather than reckless, says Sam Katz at Athlaw.

  • Fed. Circ. Patent Decisions In 2025: An Empirical Review

    Author Photo

    In 2025, the Federal Circuit's increased output was not enough to keep up with its ever-growing patent case load, and patent owners and applicants fared poorly overall as the court's affirmance rate fell, says Dan Bagatell at Perkins Coie.

  • Regulatory Uncertainty Ahead For Organ Transplant System

    Author Photo

    Pending court cases against a Centers for Medicare and Medicaid Services final rule that introduced a competition-centric model for assessing organ procurement organizations' performance will significantly influence the path forward for such organizations and transplant hospitals, say attorneys at Crowell & Moring.

  • Key False Claims Act Trends From The Last Year

    Author Photo

    The False Claims Act remains a powerful enforcement tool after some record verdicts and settlements in 2025, and while traditional fraud areas remain a priority, new initiatives are raising questions about its expanding application, says Veronica Nannis at Joseph Greenwald.

  • Opinion

    It's Too Soon To Remove Suicide Warnings From GLP-1 Drugs

    Author Photo

    The U.S. Food and Drug Administration's decision this month to order removal of warnings about the risk of suicidal thoughts from GLP-1 weight-loss drugs is premature — and from a safety and legal standpoint, the downside of acting too soon could be profound, says Sean Domnick at Rafferty Domnick.

  • Series

    Hosting Exchange Students Makes Me A Better Lawyer

    Author Photo

    Opening my home to foreign exchange students makes me a better lawyer not just because prioritizing visiting high schoolers forces me to hone my organization and time management skills but also because sharing the study-abroad experience with newcomers and locals reconnects me to my community, says Alison Lippa at Nicolaides Fink.

  • FDA's 2025 Enforcement Scorecard Highlights Data Focus

    Author Photo

    The U.S. Food and Drug Administration's increased enforcement activity in 2025 was driven by artificial intelligence and a focus on foreign manufacturers, necessitating proactive compliance strategies for an environment that is increasingly reliant on data, say attorneys at Reed Smith.

  • How A 1947 Tugboat Ruling May Shape Work Product In AI Era

    Author Photo

    Rapid advances in generative artificial intelligence test work-product principles first articulated in the U.S. Supreme Court’s nearly 80-year-old Hickman v. Taylor decision, as courts and ethics bodies confront whether disclosure of attorneys’ AI prompts and outputs would reveal their thought processes, say Larry Silver and Sasha Burton at Langsam Stevens.

  • Navigating Privilege Law Patchwork In Dual-Purpose Comms

    Author Photo

    Three years after the U.S. Supreme Court declined to resolve a circuit split in In re: Grand Jury, federal courts remain split as to when attorney-client privilege applies to dual-purpose legal and business communications, and understanding the fragmented landscape is essential for managing risks, say attorneys at Covington.

  • How AI Drafting Should Transform Patent Filing Strategies

    Author Photo

    As agentic artificial intelligence reduces the time and expense required to draft and file patents, companies should shift focus away from rationing drafting hours and more toward governing optionality, says Ian Schick at Paximal.

  • 5 Advertising Law Trends That Will Shape 2026

    Author Photo

    The legal landscape for advertisers will grow only more complex this year, with ongoing trends including a federal regulatory retreat, more aggressive action by the states, a focus on child privacy and expanded scrutiny of "natural" claims, say attorneys at Reed Smith.

  • Cannabis Industry Faces An Inflection Point This Year

    Author Photo

    Cannabis industry developments last year — from the passage of a new wholesale tax in Michigan, to an executive order accelerating the federal rescheduling process — presage a more mature phase of legalization this year, with hardening expectations and enforcement to come, says Alex Leonowicz at Howard & Howard.

  • Series

    Fly-Fishing Makes Me A Better Lawyer

    Author Photo

    Much like skilled attorneys, the best anglers prize preparation, presentation and patience while respecting their adversaries — both human and trout, says Rob Braverman at Braverman Greenspun.

  • 4 Ways GCs Can Manage Growing Service Of Process Volume

    Author Photo

    As automation and arbitration increase the volume of legal filings, in-house counsel must build scalable service of process systems that strengthen corporate governance and manage risk in real time, says Paul Mathews at Corporation Service Co.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.